Xeris Biopharma Holdings, Inc. (XERS)
9.08
-0.17
(-1.84%)
USD |
NASDAQ |
Oct 02, 16:00
9.085
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Gross Profit Margin (Quarterly) : 83.47% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.47% |
| March 31, 2026 | 84.02% |
| December 31, 2025 | 84.08% |
| September 30, 2025 | 81.57% |
| June 30, 2025 | 79.58% |
| March 31, 2025 | 80.97% |
| December 31, 2024 | 79.72% |
| September 30, 2024 | 69.96% |
| June 30, 2024 | 78.15% |
| March 31, 2024 | 78.64% |
| December 31, 2023 | 76.84% |
| September 30, 2023 | 77.42% |
| June 30, 2023 | 72.99% |
| March 31, 2023 | 75.81% |
| December 31, 2022 | 72.84% |
| September 30, 2022 | 73.18% |
| June 30, 2022 | 70.28% |
| March 31, 2022 | 59.30% |
| December 31, 2021 | 75.55% |
| Date | Value |
|---|---|
| September 30, 2021 | 67.97% |
| June 30, 2021 | 58.42% |
| March 31, 2021 | 74.83% |
| December 31, 2020 | 52.50% |
| September 30, 2020 | 67.03% |
| June 30, 2020 | 20.23% |
| March 31, 2020 | -18.01% |
| December 31, 2019 | -6.38% |
| September 30, 2019 | -8.31% |
| June 30, 2019 | 22.50% |
| March 31, 2019 | 45.97% |
| December 31, 2018 | 78.28% |
| September 30, 2018 | 99.14% |
| June 30, 2018 | 90.48% |
| March 31, 2018 | 72.05% |
| December 31, 2017 | 88.44% |
| September 30, 2017 | |
| June 30, 2017 | 93.45% |
| March 31, 2017 | 89.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Zevra Therapeutics, Inc. | 95.36% |
| Aclaris Therapeutics, Inc. | 10.80% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -4.51% |
| Return on Invested Capital | -6.51% |
| Profit Margin (Quarterly) | -33.77% |
| Operating Margin (Quarterly) | 5.62% |
| Return on Net Operating Assets | -6.50% |